Home / Transcripts / Spirax Group plc (SPX) · August 8, 2024

Spirax Group plc (SPX) Earnings Call Transcript

August 8, 2024

London Stock Exchange GB Industrials Machinery earnings 89 min

Earnings Call Speaker Segments

Nimesh Patel executive
#1

Good morning, everyone, and welcome to the presentation of our 2024 First Half Results. Nimesh Patel here, Chief Executive of Spirax Group. Phil Scott, our Interim Chief Financial Officer, is with me today. Louisa Burdett is also here in the audience; she became our new Chief Financial Officer when she joined the group in July. This year's first half proved more difficult than we expected. Our financial results came in slightly under our plans. And for the rest of 2024, we have adopted a more cautious outlook. Group organic sales growth overall was 1.3%, which mirrors a softer macroeconomic backdrop across key markets during the first half, China especially. Forecasts for industrial production growth in China differ widely from one provider to another, and they have shifted substantially and frequently. So we concentrated on global IP excluding China, which rose 0.8% in the first half. Set against that, our group organic sales growth excluding China was 2.7%, which puts us well ahead of IP. In STS, China accounts for nearly 20% of sales and ranks among our most profitable operations, and there sales and margin on an organic basis were lower. ETS grew organically, helped by ongoing demand for electrification of thermal energy and by delivery of operational improvements that raised manufacturing throughput, and all of this supported the Industrial Process Heating division.

Nimesh Patel executive
#2

Demand for semicon in the Industrial Equipment Heating division has not yet picked up, even though our customers are indicating that orders will return to growth by the end of the year, which would affect sales only next year. Watson-Marlow also rose on an organic basis, and we have observed early indications that Biopharm demand is improving, which is encouraging, but a material recovery in sales is not something we expect in the second half. Our adjusted operating profit margin declined organically, with progress at ETS offset by STS. We held to our cost discipline, while at the same time preserving investment in our sales and manufacturing capabilities so as to sustain and enhance our future growth. We encountered material FX headwinds during the first half, which led to reported sales falling 3% and adjusted operating profit falling 6%. Reflecting our confidence that the group will return to high levels of growth, we are declaring an interim dividend of 47.5p, an increase of 3%. Now I have referred to the challenging macroeconomic environment in the first half. So I will explain the trends in industrial production growth for IP and set out what we expect for the remainder of the year. Global IP was weak all through the first half. And in the second quarter of the year, it was weaker than forecast at the time of our May trading update.

Nimesh Patel executive
#3

Looking at key markets like Germany, France and the U.S., which make up nearly 40% of group sales, IP declined during the first half, with the biggest drop being minus 4% in Germany. As the table illustrates, second half IP has seen substantial downward revisions, especially across Europe and the Americas, and China's second half is expected to come in materially below the first half. Even though estimates keep getting cut, a sizable recovery is still projected for global IP growth excluding China, moving from 0.8% in the first half to 1.6% in the second half. We stay cautious on that outlook, especially regarding how big this forecast improvement is. So we've adopted a more conservative approach in planning for the second half, assuming a smaller IP improvement over the first half, and our guidance reflects this. With that, I'll pass it to Phil to walk you through the financials before I return to cover operational performance.

Phil Scott executive
#4

Thanks, Nimesh, and good morning, everyone. So, as usual, the figures we'll be going through today are the adjusted results. There's a full reconciliation between the statutory and adjusted operating profit included as an appendix to today's presentation. And just as a reminder, the gap between our reported and organic growth rates comes from the effect of currency movements on sales and profit. Those impacts show up in our reported numbers, but they're excluded from our organic growth rates. So, as we said in March and again at our trading update in May, currency movements represent a material headwind of 4% to our first half sales and 6% of profit. That reflects sterling strengthening materially versus the comparative period in 2023. While reported group sales were 3% lower in the first half than in the same period last year, this decrease was impacted by the exchange rate headwind of 4%. On an organic basis, sales increased by 1%, reflecting the increases in ETS and Watson-Marlow, being partially offset by a decline in STS. Group operating profit declined 7% or 1% on an organic basis to GBP 160 million, a decline of 2% in STS, driven by the lower sales, more than offset organic growth in both ETS and Watson-Marlow.

Phil Scott executive
#5

The drop in operating profit, together with the resulting mix of group sales and profit, produced a margin of 19.4%, down from the equivalent period in 2023. Net financing costs rose to just under GBP 22 million, which mirrors the effect of elevated market interest rates on fixed rate debt reaching maturity that we refinanced during last year's second half. As we guided in March, the group's effective tax rate went up by 110 basis points. That rise mirrors the profit mix across the countries where the group operates, including the effect of exchange rate movements, plus the first year of the BEPS Pillar Two minimum tax rate adjustment. Adjusted EPS came in at 137.2p per share, 12% lower, a steeper decline than operating profit because of the higher net finance expense and effective tax rate. As Nimesh said, the interim dividend is going up by 3%, which mirrors our guidance for stronger trading in the second half and our confidence in the resilience of our group. Turning now to the sales bridge. As mentioned earlier, you can see the material exchange rate headwind of GBP 34.5 million, or 4%, on sales. Against a very strong growth comparator of 15% in 2023, organic sales in our Steam Thermal Solutions business dropped by 1%.

Phil Scott executive
#6

The decline this fall came from IP contraction across several of our major markets, as Nimesh pointed out, along with a softer macroeconomic picture in China that hit large projects funded through our customers' capital budgets. In China during the first half of last year, we saw a benefit from catch-up spending after COVID-19-related lockdowns eased. That included the tail end of capacity expansion in pharma plus rising demand from the EV battery sector, where we've established a strong position. In this half year, fewer large project sales in China were affected by tariffs on EV exports, which led to weaker demand from the battery sector especially. Organic sales growth at ETS for the half year was 5%. Strong growth in industrial process heating — made up of our Chromalox and Vulcanic businesses — supported this. We keep benefiting from robust demand for decarbonization solutions and from better throughput at Chromalox' manufacturing facilities. At our Thermocoax and Durex Industries businesses, organic sales growth in Industrial Equipment Heating remains affected by soft Semicon demand. Sales at Watson-Marlow grew 3% organically. Although we've seen a few early signs that year-on-year demand from biopharm customers is improving, that hasn't yet turned into meaningful sales growth.

Phil Scott executive
#7

Revenue from customers in Process Industries tracks IP far more closely, which means organic growth got held back by the somewhat soft macroeconomic backdrop. Today's next bridge walks through the changes in adjusted operating profit and adjusted operating profit margin across the 6-month period. Once again, currency effects weighed on profit, this time to the tune of more than GBP 10 million, or 6%. Both translational and transactional impacts drove that. Within Steam Thermal Solutions, profit declined 2.4% on an organic basis, mirroring the organic sales decline along with adverse mix effects from lower sales in our higher-margin China business. As a result, the adjusted operating profit margin in STS dropped 90 basis points, or 30 basis points organically, to 23.5%. At ETS, profit rose by GBP 3 million, or 12% organically, driven by strong progress across our Industrial Process Heating divisions, partly offset by the adverse mix effect of lower higher-margin Semicon sales in industrial Equipment Heating. The ETS margin expanded organically by 80 basis points, reaching 14.7%. Rising manufacturing volumes at our Chromalox sites are backed by ongoing investment in people, processes and operating efficiency initiatives, which also help us get ready for completion of the expansion project in Ogden during the first half of next year.

Phil Scott executive
#8

Watson-Marlow delivered organic profit growth of 2.4%, where gains from organic sales were partly offset by a full 6 months of costs tied to our new U.S. manufacturing site in Massachusetts. Consequently, Watson-Marlow's adjusted operating profit margin came in flat versus the first half of 2023, at 24.6%. Corporate expenses, measured as a percentage of group sales, rose slightly year-on-year, driven by continuing investment behind key strategic initiatives, including the development of digital solutions for customers. At the group level, adjusted operating profit margin declined by 80 basis points, or 30 basis points on an organic basis, which reflects the mix impact of weaker sales in higher-margin countries along with the overall sales and profit contribution from each of our 3 businesses. Moving on to cash flow: our operating profit to cash conversion rate stood at 53%. That was broadly in line with what we expected, although capital expenditure came in slightly below forecast. CapEx for the first half was 5% of sales. The shortfall stemmed from changes to the phasing of payments on ongoing large capital projects, as well as the sale of an existing building in Australia, whose proceeds lowered our net CapEx spend.

Phil Scott executive
#9

During the opening six months, working capital went up, which is what we normally see at that point in the year. We still expect money to come in over the latter six months, and that should bring our ratio of working capital to sales back in line with where it has historically sat at year-end. Looking at the whole year, we still expect cash conversion of roughly 75%, consistent with what we told you earlier in the year. After paying the final 2023 dividend, we finished the period with net debt of GBP 718 million, equal to 1.9x EBITDA. Thank you. I'll hand it back to Nimesh now.

Nimesh Patel executive
#10

Thanks, Phil. Over the 6 months since I took on the CEO role, I've finished a thorough set of visits to our local operating companies worldwide and across all 3 of our businesses. I've also had conversations with customers and with colleagues throughout the group. What I've aimed for is a fresh, objective look at the Spirax Group, done together with my executive team, and I'll soon be sharing some early thinking with you about our commercial, operational and financial priorities. But where action was needed, we haven't waited to seize the opportunities we've spotted. So during the past 6 months, we've made progress on a number of fronts, and I'll take you through these on the next 2 slides. First, building on our commitment to keeping our colleagues safe, we implemented mandatory safe operating practices for machine guarding across the group for the first time. I've made changes to our executive leadership team. Armando Pazos, MD of ETS, will leave the group at the end of August, and Andrew Mines, currently the MD of Watson-Marlow, will succeed him. I'd like to thank Armando for what he's contributed to ETS, including his leadership of the Vulcanic and Durex Industries acquisitions.

Nimesh Patel executive
#11

I'd also like to express my appreciation to Andrew for stepping into this new position. He comes with a wealth of experience running manufacturing and sales operations based in both the U.S. and Europe, along with strong leadership capabilities, and that will help drive closer cooperation and integration across the 4 acquisitions that make up ETS. The process of finding someone to fill Andrew's role is already underway. We put money into the areas that will drive our growth going forward. Only this week, we reached an agreement to put in EUR 4 million for an initial 12% stake in a German technology start-up that is breaking new ground in the development of high temperature heat pumps. We hold an option to raise our holding, bringing this technology into our Target Zero Solutions portfolio to electrify steam generation, with a focus on critical high-temperature applications where steam is used directly in our customers' industrial processes. I'll go into more detail on that later when I talk about our ambition and our unique capacity to help customers deliver on their decarbonization goals. We've also kept lowering our Scope 1 and 2 emissions, which were down 9% in the first half of the year, and we remain well on track toward our goal of a 50% reduction in emissions versus our 2019 baseline by 2025. And during the past 6 months, our teams have adjusted to internal changes while also steering through and reacting to a tougher macroeconomic environment.

Nimesh Patel executive
#12

So I want to express my appreciation to my teammates for the enthusiasm they keep bringing and for all their effort. Moving on now to how operations are progressing in our businesses, and I'll begin with STS. At STS, both sales and margin fell on an organic basis, largely because of China, where roughly 20% of sales come from our high-margin operations, and where demand dropped 12% during the first half, all of it attributable to fewer large projects, as Phil explained. Large projects make up about 15% of group sales, yet they represent a far bigger portion of STS sales in China, consistent with the prior pattern of customers adding production capacity as their exports grew. Going forward, our team on the ground is working to shift away from a heavier dependence on big expansion projects and toward process optimization and MRO, though that shift will take time. Turning to our end markets, sales into our bigger target sectors — food and beverage, oil and gas, and chemicals — which make up more than 30% of STS sales, rose organically in the first half, showing the ongoing payoff from our sectorized go-to-market strategy. Now to our strategic drivers. As I said earlier, we invested in emerging high temperature heat pumps, and that will expand our Target Zero suite of solutions.

Nimesh Patel executive
#13

We're also running pilots of ElectroFit, our technology that retrofits steam-generating boilers, and we're on the verge of starting a pilot of SteamVolt, which is the first-fit version of steam-generating boilers, done in partnership with boiler OEMs. Turning to ETS. Our order book in Industrial Process Heating is still at historically high levels, with ongoing demand for our Thermal Energy Electrification Solutions, which help customers meet their greenhouse gas emission goals. Industrial Process Heating was the main driver of solid organic sales growth in ETS, and we've begun delivering operational improvements, raising throughput at our manufacturing facilities and cutting lead times on customer deliveries. That continues to be a key priority for us, especially at the Ogden facility, given the role it plays in making large, bespoke, low-voltage and medium-voltage heaters to serve global demand. We now have a detailed understanding of the issues that held progress back historically, and we've taken concrete steps to build an improvement path, including appointing a new head of manufacturing in ETS and a General Manager in Ogden. The early progress on throughput is encouraging and will keep supporting ongoing ETS margin expansion. And just as a reminder, this is one of the most important self-help opportunities we have and a key component of moving ETS margins toward our 20% target.

Nimesh Patel executive
#14

We're aiming to generate value from the acquisition we recently made in Industrial Process Heating by bringing our regional sales teams and the leadership of our worldwide manufacturing sites together under a new organizational structure spanning Vulcanic and Chromalox. When it comes to Industrial Equipment Heating, sales haven't yet picked up from a demand recovery in the higher-margin Semicon sector. Customers are indicating strong expectations that they'll place more orders in late 2024, but that mostly flows through to our sales in 2025. As a result, we don't expect a meaningful Semicon sales recovery this year. Illustrations of growing collaboration within Industrial Equipment Heating include moving Thermocoax's U.S.-based production over to Durex Industries, and we're drawing on the combined team's expertise in our new product development projects. So through leadership changes as well as organizational changes, you can see how we're concentrated on generating value from the acquisitions we recently made in ETS. And last, turning to Watson-Marlow. We achieved organic sales growth across both the Biopharm and Process Industry sectors. We've observed some early signals of improving demand from Biopharm customers, which is encouraging. As those customers take shipments of orders placed in earlier years, we're also continuing to see our order book normalize toward a lower historic level while sales keep running above order intake.

Nimesh Patel executive
#15

For Biopharm, we aren’t anticipating any material sales increase during the second half; a recovery now looks more likely later this year than we had previously expected, though predicting the exact path remains difficult. In April, we introduced Watson-Marlow Architect solutions for Biopharm customers, and traction has been strong. That illustrates self-generated solutions selling: a bespoke offering that lets customers link disparate systems and equipment across the fluid path while safeguarding the safety and integrity of their processes. Process Industries delivered organic growth, even though demand was held back by the weak IP environment, with strong expansion in wastewater, food and beverage, and mining, partly offset by softer demand in our industrial sectors. Given the difficult demand backdrop and our need to manage the cost base, we reviewed Watson-Marlow’s manufacturing footprint in the U.S.A. and consolidated 2 small facilities into our new Devens facility. In the first half, we also advanced our digital ambitions by starting a pilot of a machine learning pump in mining. This technology is intended to reduce process downtime via preventative maintenance alerts that draw on monitoring of fluid parameters through the pump. I’ll now briefly lay out our outlook by business and for the group.

Nimesh Patel executive
#16

Turning to STS: for the entire year, we expect organic sales growth in the low single digits, fueled by our typical seasonality and a greater IP than we saw in the first half. As we mentioned in March, margins will come in below last year's record 24.6%, which reflects significant currency headwinds, a smaller contribution from our high-margin operations in China, and the partial reversal of temporary cost containment measures implemented in 2023, as we continue investing in our future growth. Within ETS, we expect that ongoing operational improvements in Industrial Process Heating, together with sustained strong demand for electrification products, will drive additional growth in sales, profit and margin during the second half. In Industrial Equipment Heating, we do not expect any meaningful recovery in higher-margin Semicon sales through the remainder of the year. Thus, for ETS overall, we anticipate mid-single-digit organic revenue growth along with continued margin progress. And at Watson-Marlow, we expect organic growth to continue in the second half, compared against the weak prior-year comparator. In Biopharm, as I noted, demand has displayed some early indications of improvement, though we now anticipate lower sales growth than previously expected. Consequently, for Watson-Marlow, we expect mid-single-digit organic revenue growth across the full year, with incremental sales flowing through to profit at a high rate, which supports margin progress.

Nimesh Patel executive
#17

Pulling all of this guidance together for the group, we consequently expect organic growth in the second half to come in stronger than the first half, and that will underpin mid-single-digit organic sales growth across the full year. We also anticipate the adjusted operating profit margin landing in line with the 20% on a currency adjusted basis that we delivered in 2023, which reflects our sales mix — with lower sales from higher-margin STS in China, a greater share of group sales coming from ETS, and the partial reversal of the temporary cost containment measures taken in 2023. Strong FX headwinds are expected to persist as well, consistent with Phil's guidance. Turning now to the medium and long term, let me bring you up to date on some of the work underway. We are planning a Capital Markets presentation in October, at which we will set out our longer-term commercial, operational and financial priorities. Today I would like to share some early thoughts with you, which, as I said earlier, are shaped by the time I have spent in our local operating companies and with my colleagues. My aim is to view the Spirax Group through a different lens and to educate myself by listening. Together with my new executive team, we have tried to take a fresh and objective look at our group so as to assess our strengths, what we can do better, along with our opportunities and how we must adapt.

Nimesh Patel executive
#18

So through this process, this is how I view the Spirax Group and what we do well today that we'll preserve. Our products, solutions and expertise are critical to our customers' operating efficiency and safety in industrial thermal energy and fluid technology processes. Our organic growth and industry-leading margins come through a unique business model: engineer-led direct sales, a focus on consultative solution selling, and pricing based on customer economics. We benefit from being highly diversified across geographic regions and sectors, with a high proportion of sales from defensive end markets. And because our sales are mostly funded from customers' operational budgets rather than their capital expenditure. Looking ahead, I believe the value we have delivered to our customers over the past 136 years remains just as relevant today. But importantly, and additionally, we can and will benefit from new structural drivers of growth. Through our end market and sector exposures, we are attractively positioned, thanks to the work of my predecessor and through the fundamental strengths, which I've just described. But we recognize there is work to do to get after these opportunities by targeting investments towards new growth drivers and focusing on the opportunities we have to self-help, operational improvements that we can make to help us be both more effective and more efficient, helping us to fund the investments we need to make.

Nimesh Patel executive
#19

By taking these steps, I am confident we can speed up our long-term compounding organic growth at appealing margins. And as the first half results made clear, we aren't sitting back before pursuing these opportunities. We've taken some difficult decisions regarding people. We've put money where it matters for our future in spite of the tough environment, and we're pushing manufacturing improvement and consolidation. So this morning I want to cover 4 things. How strongly placed we are to take advantage of 4 key global trends that are reshaping our customers' businesses. Those trends are the growth drivers for us as we get ourselves ready to serve their future needs. How we are concentrating investment on growth opportunities that will help us deepen our ties with our customers. How we're picking up the pace on delivering operational improvements via self-help programs and what that means for our growth. Those 4 points come together in our work to build a new group strategy, aligning around a shared set of objectives for our businesses, keeping what we do well and concentrating on self-help and growth drivers. This is what we call evolving for tomorrow's world. We are working to position Spirax Group to gain from global trends that will fuel our long-term compounding growth for decades to come.

Nimesh Patel executive
#20

Let's begin with the emerging middle class—defined by more than 800 million additional people, mostly in Asia and Africa. Consumption will rise because of this group, affecting food and beverage and energy and power as well as mining—sectors that today make up over 1/3 of our sales. As demand grows, the first need will be process efficiency and productivity improvements; the second will be capacity expansion throughout our customers' operations—all areas where we are a leader. Turning to resource efficiency and sustainability: our customers are setting targets to reduce greenhouse gas emissions and water use. Industrial thermal energy today represents 20% of global carbon emissions, comparable to global transportation. Reducing energy waste is what STS has done for over 100 years, developing a deep understanding of our customers' industrial processes. The unique combination we have of STS and ETS, and our products that reduce customers' carbon dependency through electrification of thermal processes, is a powerful differentiator for the Spirax Group in developing decarbonization solutions. Both for the generation of steam, which tackles 30% of all industrial carbon emissions, but also through electrification of thermal energy generated from burning directly fossil fuels, accounting for a further 60%.

Nimesh Patel executive
#21

With our electrical-thermal energy know-how in ETS, we're also helping the nuclear and energy industries grow as the world reduces its reliance on fossil fuels. And in Watson-Marlow, we're out front in the wastewater segment. The next worldwide trend—an aging population around the globe—will require more healthcare services, with pharma and biotech plus healthcare making up nearly a 1/4 of our sales, mainly in STS and Watson-Marlow. Over the coming decade, 1 in 6 people worldwide is projected to be 65 or older, taking that global group to 1.5 billion people, close to twice what it is now, and we'd expect this older generation to be considerably wealthier than the younger ones coming after them. That's driving innovation in Biopharm to create and make new treatments. Via Watson-Marlow, we're already a world-leading supplier of products and solutions to Biopharm, which is expanding at above 10% per annum. And last, we're investing as well to widen our addressable market in other growing sectors shaped by changing lifestyles. For instance, via our Industrial Equipment Heating division in ETS, we're a top provider of essential thermal energy solutions to Semicon.

Nimesh Patel executive
#22

Watson-Marlow is establishing a foothold in the future food sector, and that includes collaborating with cell-based protein start-ups as they try to tackle worldwide food shortages via more sustainable production, using technologies that sit very close to Biopharm. And in the complex manufacturing chain for electric vehicle batteries, both STS and Watson-Marlow have likewise established a presence. Taken together, these 4 trends highlight our growth potential, thanks to the structural appeal of the end markets we already serve and the room to broaden our addressable markets, and that is how we will maintain and speed up our compounding growth across decades. So let's turn now to how we intend to aim our investment in these big, expanding addressable markets to reinforce the ties we already have with customers by delivering solutions to the problems that matter to them. And across STS and ETS, we are uniquely positioned to shape the energy transition choices our customers face, through the trust we have built with them, our technical expertise and our process insight. Over several years, this energy transition will affect our businesses in multiple ways. So beginning with decarbonization of steam, helping customers optimize how they use steam, and thus their energy consumption, has been our focus for a long time, historically to cut costs, and now to cut emissions as well.

Nimesh Patel executive
#23

That isn't new, though it does matter. What is new would be the expanding lineup of TargetZero products and solutions that solely we, as a group possessing expertise in both steam and electric thermal areas, are able to deliver. Thus, for instance, as I mentioned before, we are running pilots of our first-of-all products aimed at decarbonizing steam generating boilers at customer sites. And while we gain insight from those pilots, we keep advancing this technology prior to full commercialization. And as you heard, we are chasing new technologies to expand our range of solutions so that a more comprehensive offering reaches our customers. So high temperature heat pump technology broadens our electrification products further, but allow me to explain briefly why that matters. High temperature heat pumps are going to be used in critical applications where steam is employed directly within our customers' industrial processes — essentially our target niche. This will be a highly engineered, bespoke technology, enabling our customers to recycle waste process heat in order to generate steam while cutting their operating costs and carbon emissions. This differs from hot water heat pumps, which are a commodity technology used in low temperature applications that contribute towards decarbonization in less critical processes and usually alongside existing steam systems.

Nimesh Patel executive
#24

By turning ourselves into more of a solutions provider for our customers, we'll be in the strongest position to guide them on the full range of technologies out there and on which ones suit their process needs best, while still hitting their targets for cutting emissions. One thing is clear: decarbonizing steam generation means a substantial widening of our addressable market. To deliver that capability successfully, we're currently at work designing an operating model that unites customer insight with sector-based expertise from across STS and ETS around steam decarbonization, and we'll build on what we already do in design engineering and in manufacturing bespoke products. Second, a wider scope for electrifying thermal energy, going beyond heavy steam users, gives us a chance to help customers lower their carbon emissions, and that chance is significant. Via the Industrial Process Heating division of ETS, we hold a leading competitive position already, along with innovative technologies like medium voltage offerings, but further R&D investment is needed so our technology can expand. Take, for instance, the development of higher temperature elements and of products able to run at higher voltages — every one of these will grow our addressable market opportunity. Now on to digital. We're putting investment into technologies that speed up delivery of our business model by strengthening customer bonding founded on deeper insights.

Nimesh Patel executive
#25

With digital, our direct sales engineers can tap into data from customer processes more often, putting their expertise to work — and that leads to more solutions plus a stronger ability to show the economic value we bring them. Beyond that, naturally, we'll put investment behind organizational capability, cultivating fresh skills and new working methods required to meet customers' changing needs. Hearing my colleagues talk about the group and our current position has also made it plain that self-help room exists — meaning how we rank operational improvement opportunities and then speed up delivery. The areas I think demand our attention, the ones that let us shore up our foundations, take in sharing best practice throughout our geographies and businesses so execution of our business model is embedded further, lifting the share of revenues coming from self-generated solutions, and sharpening our grasp of customers' evolving needs so our competitive advantage grows. Also on that list: making manufacturing facilities more efficient across all 3 businesses — not something previously prioritized, since the group saw high growth and high margins.

Nimesh Patel executive
#26

We're cutting down the organizational complexity that built up as we grew from fewer than 70 operating companies to more than 140, and we're strengthening systems and processes throughout the group to tackle areas where we underinvested in the past, and we're getting value out of ETS by concentrating on operational improvements and integrating the 4 acquisitions, gaining from better collaboration and the potential for revenue synergy. These self-help efforts will help us fund our future growth, and we'll say more about them in October. But what does that mean for our growth? Through the steps I've laid out, over the long term, I think we can speed up the pace at which we deliver, compounding organic growth in sales and profit. I've described some of the areas where we'll need to invest to realize this potential, and our growth will fund that investment. And of course, this transformation won't happen overnight. Over the medium term, we can maintain our solid historical track record of mid-single-digit organic sales growth and mid- to high single-digit organic profit growth. And while STS remains a very high-quality business, today our faster-growing businesses, ETS and Watson-Marlow, represent close to 50% of group sales. So the mix of sales and profit growth across our 3 strong businesses will differ from the past.

Nimesh Patel executive
#27

There's also a significant self-help chance for us to boost both topline and bottom line growth, while building capacity for investment and lifting our adjusted operating profit margin into the 22% to 23% range. Organic profit growth, paired with stewardship of our invested capital via capital discipline, working capital efficiency and robust cash generation, will likewise produce improving returns on capital. I appreciate your time. Thanks for listening to me. I'll gladly take your questions. And may I encourage everyone to look through the detail contained in our half year release? Thank you.

Nimesh Patel executive
#28

I think we'll begin with Andy. Yours was the first hand that went up.

Andrew Douglas analyst
#29

Andy from Jefferies here. May I take a slightly contrarian stance regarding the strategic update released today? I completely understand that high temperature heat pumps are an entirely new item—I've never previously heard you mention them. Yet when it comes to the long-term geographical macro trends involving decarbonization and digital, those are essentially topics you've discussed for years. So is the situation simply that efforts you've pursued over the past however many years are now materializing to fuel growth? Or does this amount to little more than a rebranding of what you'd already presented as a major strategic update? To me, it seems there isn't much that's genuinely new in it.

Nimesh Patel executive
#30

What's new, then? The answer to that comes down to how we pursue certain opportunities. In the past, our thinking ran along the lines of TargetZero being a set of highly exciting products designed to help customers electrify the generation of steam. As you likely recall, the TargetZero suite contains 3 products. The first was an electric boiler for first-fit applications, the second was a retro-fit option for a steam generating boiler already in place, and the third was a thermal energy battery that basically stores thermal energy as steam. Those remain important, but our conversation now extends past them. First, we're asking how we shift from supplying these discrete solutions to serving as a partner to our customers across the full suite of their industrial processes and the challenges they must contend with in order to reach their Net Zero targets in the end. That calls for a far more holistic relationship with those customers, one that pulls together expertise found in various parts of our group along with expertise our group does not have today. High temperature heat pumps are one instance of adding something entirely new that widens that range and puts us in position as a true consultative partner for our customers, with access to a broader array of solutions and the ability to advise them better on how they get to zero.

Nimesh Patel executive
#31

So the way we go about it is quite different. And since our execution approach differs, that opportunity's size expands. The second point that perhaps not everybody has completely grasped yet is that a huge opportunity exists beyond just decarbonizing steam. When you consider total thermal energy, steam accounts for 30% of industrial process needs, yet 60% stems from burning fossil fuels directly, which must be electrified. That's a genuine opportunity for ETS. Which means we have to expand that business. We have to build up our sales capabilities. We have to increase our manufacturing capacity. We have to expand into new regions across the globe. That's a very substantial extra opportunity requiring considerable investment. The third item is digital. So the manner in which we're going after digital is also probably going to transform our business. We've discussed capturing customer data and leveraging it to improve how we serve them under our current business model. But in fact, digital carries us past that. Digital might move us into considering services and how we create various services alongside the products we provide to customers.

Nimesh Patel executive
#32

That can strengthen our ties with them and provide far clearer understanding of how their challenges are evolving—not merely the ones we’re able to address today—so we’re better placed to have our business ready to handle those challenges. So basically, over the last 6 months, have the major worldwide trends that fuel growth, not only for us but for so many companies across the globe, have they shifted? No, they haven’t. So that part remains unchanged. What is different is, I think, how ambitious we’ve become about what we can accomplish in light of those worldwide trends and how we pursue that—both in what we do and in the speed at which we do it too.

Andrew Douglas analyst
#33

Regarding ETS, management over on the manufacturing side has changed. Was there something particular behind that? Or could that mean the risk there ends up moving further to the right?

Nimesh Patel executive
#34

That adjustment was implemented at the start of the year, and that's the reason I've reflected it here in the half-year figures. I did in fact discuss it back in March. So just to be clear, this isn't an additional change layered on top of that one. And yes, the driver behind it was the need to move forward with the operational improvement work, and it has delivered. As you can see in the results, we're beginning to witness that genuine progress coming through. And there's still more to achieve. That journey will carry us through the rest of this year and into 2025, but I want to demonstrate the ongoing progress we're making in that area.

Andrew Douglas analyst
#35

And then one final question from me. Obviously, the group will need substantial investment over the coming, say, 5 to 10 years. You mentioned systems — that dreaded word. Does that mean a major ERP rollout, the kind of hefty expense the sector has seen that has turned into something of a disaster for a few companies? Where do we stand on that, please?

Nimesh Patel executive
#36

As you're aware, ERP implementations were already underway on our side. And, as you know, we had to record a write-down on the project that was furthest along, the one in steam, which we booked last year. I'm shifting how we go about applying the ERP. Previously, we ran 3 programs spread across 3 businesses. That, in my view, isn't the right way to do it. What I believe is right is to do this jointly, learning from one another, and to achieve greater alignment across the ERPs we implement, since plenty of processes can be run the same way, yet a meaningful number of processes cannot, given the differences among our businesses. So the manner in which we carry out those ERPs will differ, and we'll fund it out of our ongoing growth. Partly we'll fund it through CapEx, while keeping our discipline. So fundamentally, nothing, I believe, has changed when it comes to us being a low capital-intensive business.

Stephan Klepp analyst
#37

Stephan Klepp from HSBC here. I've got a few follow-ups, really building on what Andy asked. So you're discussing systems, but we're also talking about capabilities, medium voltage electrification, and so on. Does that also shift the CapEx profile we ought to expect, since you mentioned investment somewhat and having the proper capabilities in place to invest? That's my first question.

Nimesh Patel executive
#38

We’re going to stay a business that doesn’t require much capital. So I expect our CapEx to be at the same level as today, or perhaps a little lower. Keep in mind that we’ve only just started a set of very large projects: constructing a new factory in Devens, Massachusetts. Right now we’re building another new factory to expand our Ogden site in Utah in the U.S. Before that, we built BioPure in Portsmouth and Aflex in Huddersfield. We’ve constructed a new Thermocoax facility in Normandy. So versus those levels, I don’t anticipate any material increase in CapEx. We remain a low capital-intensive business.

Stephan Klepp analyst
#39

Now, regarding ETS. You referenced, clearly, the cell type narrative inside the company, inside the firm. And Ogden, obviously, has been a painful area for a while now. So what I'd ask is whether you could give us a bit of assistance when it comes to sales at Ogden? Where things stand? What growth rates look like there? And what margins they're running at present? And what the potential ought to be 2 years out, the period it takes to get that business going, as you mentioned?

Nimesh Patel executive
#40

Stephan, glad to help. It might not feel like help by the time I'm finished, but we'll see. So yes, inside Ogden we have observed a significant step-up in ex-factory gate sales. And because of that, margins have improved. Are we where we want to be? No. There is certainly more work to do. These problems are complex. It isn't as simple as having a manufacturing facility with a challenge in it that we need to fix. It's about how the entire process operates from end-to-end. So it means thinking about how we engage the client. Keep in mind, these are highly bespoke products. Which level of bespoking is valuable to the client and to us, and which amount of bespoking isn't? So we need to build that muscle to ensure we've understood clearly upfront in the process what it is we're committing to. We then — since this is different for our group, not so different within Ogden, but for the rest of our group, this is different. This isn't so much what we've grown up doing. We then need to ensure we have the right processes and understanding. Once that order has been taken, how do you continually engage the customer all the way through?

Nimesh Patel executive
#41

Since changes are constant—whether they're modifications the customer requests, shifts in the materials on hand, or differences in how the product will ultimately be used—we have to stay aligned with how our customer thinks, with their grasp of what we're doing and how it fits what they need. So there's a genuine project management capability that has to be developed there. We have to confirm we have the right design engineering skills, so those concepts can be converted into drawings that are manufacturable on the shop floor. That calls for technologies we haven't yet fully put in place today when it comes to the tools used for that work. Then you must ensure the entire chain—all the way through to manufacturing—is connected. People are in constant communication with one another. So it's a more complicated undertaking. We've achieved real progress on the manufacturing side. Progress is being made on the design engineering side. We've also advanced on the project management side. And now we're tying all of it together. And naturally, the great news here is that this is within our control, because at the end of the day, the demand is still there.

Nimesh Patel executive
#42

Demand keeps rising. So once we nail this, it’s really going to help us speed up the growth we’re seeing in ETS.

Stephan Klepp analyst
#43

This is likely my final question, FX, so it feels a bit like Groundhog Day 2014-'15, and I would rather like to know is anything changing with regard to elasticity. I don't want the FX forecast here. I'm rather thinking ETS is new to the mix. Is it rather accelerating or magnifying the problem with FX and the sensitivities you are having in the group?

Nimesh Patel executive
#44

So the question you're raising isn't really about how demand responds to FX — it's about mix inside our group, right?

Stephan Klepp analyst
#45

With ETS newly joining the picture, that item comes last, and it's driven by the issues you raised.

Nimesh Patel executive
#46

On a reported basis — that is, after FX — yes, there will be an effect, and probably more so at the margins. Take STS, for instance: we face a larger FX headwind there. Why is that? It's because that business sits in far more emerging markets compared with the other 2 businesses. So what you'd expect is possibly a smaller share coming out of STS, and as a result, a matching rise in the portion of the total contributed by the other 2 businesses. And probably more so — you're right — from ETS, given that it's based in North America and Europe. I think that's what gets reflected when we discuss our margin being affected by the group's sales mix as well. Jonathan, I believe, was next. Yes.

Jonathan Hurn analyst
#47

Jonathan Hurn here, from Barclays. I've got 3 questions. First one is about that new Watson-Marlow facility in the U.S. Clearly, there were costs tied to it during the first half that obviously <<inaudible>>. How much did those costs come to? What should the costs be in the second half? And do they actually carry on into FY '25 as well?

Nimesh Patel executive
#48

Right. I don't believe we've shared the exact dollar figure for that cost, but I think Phil can give you a sense of it — a sense of what the cost looks like.

Phil Scott executive
#49

Allow me to lay out for you the shape — let me try to give you the shape of the margin profile at Watson-Marlow as well. So if we look at that Watson-Marlow profile across roughly the last 3 halves in sequence, there have been a couple of one-offs that we called out. As you'll remember, during the second half of last year, we took a large inventory provision, and that artificially pushed the margin down. Regarding the extra costs we called out in this half year for the Devens manufacturing facility, you should view those as the final set of one-off costs that we would expect. So going forward, we won't be calling out any bridging items on that facility. And then the third piece is, obviously, we've had some variable compensation changes in accruals and releases, as we've trued that up against our internal targets. But the underlying message, if you look at H1 last year — H2 last year and H1 this year, and you normalize for those 3 elements I've talked about, you would see sequential progress half year on half year.

Jonathan Hurn analyst
#50

The second question was only about steam. You've clearly covered China in detail, but I'm wondering whether you could give us a bit more color on the other regions, especially the U.S. A lot of stuff there obviously goes through distributors. What are you seeing in the distributor channel there? Is there an element of destocking we're seeing? Could that happen in H2? And also, what are we seeing when it comes to European steam?

Nimesh Patel executive
#51

Let me begin with the latter portion of your question. Europe is a region where, once again, we've encountered a difficult IP climate — indeed, a contraction. You brought up Germany, and France along with the U.K. have also proven difficult within Europe. Naturally, when you combine those 3 markets, they represent a very substantial share for us. We beat IP. That's the reason I wanted to display how our figures appear once the China IP numbers are excluded — and frankly, I don't trust the China IP numbers, which is precisely why we removed them. So we beat IP. We keep beating IP across Europe and in the U.S. Yet IP functions somewhat like gravity — there's no escaping it. It will therefore always affect our business, and that is precisely what we're observing in Europe, and what we're observing in the U.S. I'm acutely conscious of discussion regarding additional economic softness in the U.S. during the second half of this year. That is why we have incorporated into our internal planning and our external guidance a more conservative assumption regarding how large the step-up in IP will be in the second half.

Nimesh Patel executive
#52

We think that, well, that's what safeguards our guidance. In the tougher IP environment we anticipate for the rest of this year, we ought to be able to deliver on it. That said, there are no guarantees, all right? Much of this is going to hinge on precisely what unfolds in the macroeconomy during the second half of the year.

Jonathan Hurn analyst
#53

And for the final question, it's fairly close to that one, I'd say. So when we look at the business, clearly there are probably 2 other businesses that are more driven by the order book — ETS and Watson-Marlow. Looking at second-half revenue for those, there's plainly a substantial step up. On how much of that revenue is covered by the order book, could you give us a sense for each of those businesses, please?

Phil Scott executive
#54

I think you're right to highlight how those 3 businesses differ. Watson-Marlow resembles STS quite closely. A fairly large share of the orders we receive in a given month are book and ship. Because of that, order coverage won't offer much reassurance for Watson-Marlow, since you have to see orders growing before sales can grow, and you'll find that timing is more aligned than you'd expect. ETS works differently. Delivery lead times there are considerably longer. Our ETS backlog stands at pretty much close to record order levels. Demand isn't the problem there. What's challenging us there is raising our manufacturing throughput and output, which is within our control. So in that case, I'm paying less attention to macroeconomics and demand, and more attention to our capacity to ramp up manufacturing through the second half, and that's what our forecast is built on.

Nimesh Patel executive
#55

I think Lush should take it from here. After that, we'll go to the phone lines, and then I'll rejoin from the room.

Lushanthan Mahendrarajah analyst
#56

This is Lush Mahendrarajah at JPMorgan. I have a few questions too. The first one concerns that midterm margin guidance of 22% to 23%. If we assume Watson-Marlow comes in around 30, in the low 30s, and ETS is roughly 20, then steam works out to somewhere in the low 20s, which, as I see it, brings it back to roughly pre-COVID levels. Given some of the points you raised about operational improvements and simplifying how the group is structured, I suppose you believe margins could end up above where they were pre-COVID. I understand there's additional investment on the way. I'm just trying to figure out that bridge — why the steam margin might be higher in the midterm.

Nimesh Patel executive
#57

Yeah. How do the margin pieces fit together? That's a reasonable question. So I'd say your analysis is broadly correct on all of those elements. I think the first 2 points I'd make. One, the more recent margins in steam are higher than I think we should expect them to be and probably than they should be. As part of a group, when we have challenges in Watson-Marlow because of the drop-off in Biopharm demand, when we have challenges in ETS, more of the burden in making sure that we continue to maintain our profitability was carried by steam. That can happen for a short period of time. It cannot happen for a long period of time. That's one of the things that we are correcting. More investment is required, not just to sustain that business and its growth, but actually to deliver against the long-term opportunities that I talked about. So that's why I think the steam margin comes back to closer to its pre-pandemic levels. The second thing, which is a sort of, I think, a bigger picture point across the group, is we need to make those investments. We want to invest more in developing the technology for TargetZero.

Nimesh Patel executive
#58

We're looking to put more money into digital. Those are excellent investments for us to make. When we execute well, the returns from these investments are extraordinarily high, thanks to the long-term compounding growth they'll drive in our business. So one of the most important judgments I can probably make in this role is figuring out the right level of profitability for this group — so that we're not under-investing, and so that we're also not frivolous with the resources that belong to our shareholders. And that's exactly what I'm setting out here in this update: I believe that margin target should fall between 22% and 23%. That's how we get the balance right. And we should remind ourselves that this is an extremely attractive level of margin across the industry.

Lushanthan Mahendrarajah analyst
#59

The next question also concerns steam—really just the latter six months, I suppose. Comparisons get simpler during that period. Part of the reason, I think, is that China was weak in the back half of last year. Obviously you've flagged the EV items and the pharma items when it comes to last year. Those are sizable orders. Did many of them land in that second half of last year, for thinking about the comparison too—or had all of that wrapped up by then, meaning the comparison is somewhat cleaner?

Nimesh Patel executive
#60

I’ll let Phil discuss the steam comps.

Phil Scott executive
#61

Right. As you may remember, during the first half of last year, steam was growing at 15% plus. So there's definitely some tough comparatives in there. And, as we hinted at — I think both Nimesh and I brought this up — the comparison for China last year, particularly on that big project that rebounded after the COVID lockdowns, was especially strong. So I think what we're looking for is a stronger H2 for steam, as you'd expect — Nimesh referred to it, and we've what I'd describe as applied an internal haircut to that IP forecast within our forecast. But if you look at the table in the RNS, you will see a meaningful uptick between H1 and H2 in IP across our key markets. And if you look at the sales split, our steam business has historically skewed toward H2. We expect that skew to persist. So I think those are the main drivers.

Lushanthan Mahendrarajah analyst
#62

And the final question is about Watson-Marlow and Biopharm specifically. From what some peers have reported, there appears to be something of a 2-tier recovery. Consumables look like they're coming back somewhat faster, while the equipment side seems a bit slower. So when you consider the pumps, the tubing, and the clamps, how would you group those into consumables versus equipment? And are you noticing different trends across those categories?

Nimesh Patel executive
#63

I think it's a good question, Lush, about how Biopharm recovery is trending — and I'd say it has less to do with the product itself and more to do with the channels. So across our end users, across our distribution partners, and across smaller OEMs, we're seeing encouraging signs of improvement. The biggest challenge — where improvement isn't showing up, and this was somewhat expected — is in our larger global key accounts. Order levels and sales there are still very, very low. In a way, that makes sense: during the pandemic, and then very swiftly afterward, because of supply chain constraints, those larger players — the ones with the greatest clout in the market and the largest balance sheets — were the ones who bought product heavily from us and from others, building up inventories in anticipation of the demand they were likely to see from their customers for increasing capacity for vaccine manufacture, and to protect themselves from those supply chain disruptions. That's where the stock is taking longer to unwind. And of course, the challenge is that because we're so small — something I think we pride ourselves on — as part of the overall supply base for these businesses, we're a little bit more of a rounding error to their overall numbers.

Nimesh Patel executive
#64

They don't truly have a clear picture of how much of our product sits in their inventory. Because of that, they don't really know how to forecast when they'll return and place an order with us. And as a consequence, we actually see a fair amount of volatility in what comes back to us from those customers. Another thing I'd mention is that there are high degrees of variation. There are some winners, and there are some losers. The good news for us is that because we're across the entire space — I mean, how many customers do we have, end users? It's over 4,000 customers — end users in Biopharm and even in the OEMs, will be present in all of those OEMs. And so the consequence of that is even though there are winners and losers, we'll be okay over the medium term because it will all balance itself out. So that's what makes this so very difficult to forecast. Thank you, Lush. Can I just — before we come back to the room, I'll come back to you, Bruno, and then I'll come to the back, can I just check? I think it's Sandra. Are there any questions on the conference line?

Operator operator
#65

<<operator_script>> At this moment, we have no questions.

Nimesh Patel executive
#66

Okay, Bruno, let’s bring you in next. I believe you were first.

Bruno Gjani analyst
#67

I’d like a bit more detail on the biopharma trends you described as encouraging. Did orders rise from Q1 to Q2 on a sequential basis, and have we also seen that improvement compared with Q4? Has the increase been steady, or have order trends been more up and down lately? The commentary in the release also suggested book-to-bill was under 1 in the first half. I’m also curious how that stacks up against earlier halves. So maybe you could share what book-to-bill was specifically for Watson-Marlow, Biopharma. I think that would help.

Nimesh Patel executive
#68

All right, I'll begin with the trend, and then I'll let you down regarding book-to-bill. On the trend, though, there's a significant degree of volatility, for the reasons I outlined a moment ago when answering Lush's question. As a result, it's hard to draw too many conclusions from a single month's or a single quarter's figures. What I can say is that we were observing a consistent upward trajectory, and that actually gave us a good deal of confidence back in May. Naturally, at that stage we had 4 months of actuals behind us, plus some sense of how May was shaping up. Since then, May is known to us, and now, clearly, we have a sense of how August is shaping up. So we now have another 3 to 4 months of data. And that trend decelerated, all right? The pace of recovery therefore shifted, which is why the guidance was updated. That said, if you step back and consider the picture across the first half, in fact, even for the year-to-date, what becomes clear is that things are getting better. That's the encouraging signal. So when I compare that with the second half of last year, the first half of last year, and the second half of the year before, where things stayed very flat essentially until the start of this year, we are now beginning to witness that improvement for the first time.

Nimesh Patel executive
#69

That's really the point we're highlighting. I think that's the positive takeaway. Regarding book-to-bill, the pattern we explicitly flagged in our release is precisely what we've observed almost each quarter all the way back to the second half of 2022. What occurred was, first, demand was strong and we shipped a great deal. Yet the volume we could ship was limited. Consequently our backlog grew quickly. I'd say it's fair to characterize it as above double the typical level you'd anticipate. So in time, that had to come down. Now, when customers cancel orders, we charge them, correct? So there's a reluctance to cancel. What we'll do instead is assist them in rephasing deliveries. But when we rephase, we apply the prevailing price rather than the price in place when they placed the order, so we raise prices too. That's how our margins are protected. So keep that in mind. It gives you a sense of how disciplined we are in managing that exposure in Watson-Marlow.

Nimesh Patel executive
#70

What we observed was that many customers initially had deliveries they were extremely eager to receive in 2022. That shifted very fast into not needing them for '23, and then very fast into not needing them for 2024. Our expectation is that roughly by the close of this year, order levels will have returned to normal. So that will have cleared through the system. What this does mean, as we noted in the release, is that orders are less — orders fall short relative to book-to-bill, to your point. So when it comes to forecasting, which is so difficult in Biopharm, order growth has to be materially higher than sales growth, okay, if forecasts are to be achieved as we look out across the remainder of 2024 and 2025. So it's simply worth keeping in mind as you consider the business.

Bruno Gjani analyst
#71

On the underlying demand side, I believe in earlier calls you—or Spirax—kept saying that underlying demand was really rather robust, expanding at a double-digit rate. I realize there are many moving parts, and perhaps assumptions could shift. Do you still believe that underlying demand within biopharma has compounded at a double-digit rate over the past 5 years? And then—fine, if that's true, and in Q4 we've returned to that normalized level, it implies how—it implies we should snap back very sharply to trend, since we've resolved the inventory problems. So by the end of this year, how far below 2019 levels are we? And do you anticipate that sharp reversion back to trend in 2025?

Nimesh Patel executive
#72

On the first part of your question—underlying growth—our view hasn’t changed at all. We discussed growth of more than 10% in the Biopharm space. And we’re very well positioned. We’re in monoclonal antibodies. We’re in recombinant proteins. We’re in cell and gene-based therapy as well as being in vaccines. So we’re in the attractive parts of that Biopharm market, the parts that are growing because they represent the future of biotechnology. So we’re absolutely confident in that underlying growth. The reason we’re confident isn’t because we read it in a report. The reason we’re confident is because we’ve got 4,000 customers that are end users, and we visit them, and they tell us that they’re confident as well. And you can see the investment actually coming back into that biotech space. That confidence is founded on real engagement. I think, Bruno, the part of your question where I’d probably say the key assumption you’re making that I’m not sure I’d be as confident—wholly as confident as you are—is that we’ll be back to normal in Q4. We expect a recovery. We expect that recovery to continue. We expect that recovery to come later in the year than originally, but we’ve been really clear that it’s so challenging to forecast the trajectory of that recovery that it’s not necessarily the case that you’re all the way back to kind of a normalized level of demand by Q4.

Nimesh Patel executive
#73

It could land in Q4 or possibly Q1 — I can't say with certainty which one. That timing is the hard part to pin down here, but it will happen.

Bruno Gjani analyst
#74

Yeah. What I was getting at is more that certain distortions exist, and because of them your revenue sits well under where underlying market demand is — maybe 25% under. Once those distortions go away and, say, inventory levels are fully back to normal in Q4 or near it, then by 2025 that means your demand — your revenue ought to come right back up to underlying demand. If it doesn't, then maybe the estimate was off — overestimated, rather — on how sharply demand has grown.

Nimesh Patel executive
#75

That's a fair point, and I'm with you. What I can't do is pin down when it happens. Whether it lands precisely in Q4 or slips a bit past that, I honestly couldn't say. Still, as far as the overall shape goes — the way you're sketching what ought to play out — you've got it exactly right.

Bruno Gjani analyst
#76

On the margin side, with that 22% to 23% midterm target, it feels like a lot of heavy lifting is required, with more investment happening in the early phases or early years, which I suppose makes plenty of sense. So would you anticipate a steady sort of year-over-year improvement toward that 22% or 23%? Or really, how should we think about 2025 margins during this phase of heavier investment?

Nimesh Patel executive
#77

Nice try on the 2025 guidance question — I have to hand it to you. At this point, though, I won't be providing guidance for 2025. What I can tell you is that reaching that margin target won't happen overnight. It's going to take time. And the second point is that the path won't be perfectly linear. Businesses simply don't work that way. What we want is for margins to progress, but in some years the improvement will be somewhat larger and in others somewhat smaller. Part of that depends on the investments we choose to make and whether they're lumpy or not. So there's a reason we framed 22% to 23% as a medium-term target.

Bruno Gjani analyst
#78

And finally, regarding ETS — I believe the release said the backlog stayed extremely high, very high. Did orders also increase during the first half for ETS?

Nimesh Patel executive
#79

We're seeing order growth.

Bruno Gjani analyst
#80

So how are competitors responding to a few of the operational difficulties you’ve run into at ETS? Would you say they’re picking up share? Or is it more that the solutions are so customized that it’s really tough for anyone to take meaningful share while you’re having trouble ramping up — or have had trouble ramping up — on production or on getting product into the market?

Nimesh Patel executive
#81

I think -- that's an excellent question. The long lead times are mainly a difficulty on our side. I spoke with a customer of ETS who had been waiting more than a year to receive their products. And they told me, as the CEO of a very large company, they asked me, why does it take so long? What's the issue? Can we -- they even offered, we'll pay, if more money is needed for investment to bring in more people, to operate more ships, we'll pay. But what will it cost? And why does it take so long? Just help us out here. And I replied, well, look, let me share just one thing with you. The product you ordered, it has been ordered from us only 3 times over the last 12 years, okay? And to the best of our knowledge, not a single one of our competitors is able to manufacture that product, okay? So it is complex. That is what takes time. But we are focused on making those operational improvements, or we'll get it to you. And in fact, we delivered it. Of course, it came later than was originally forecast, but we got it to them ahead of the schedule.

Nimesh Patel executive
#82

We literally delivered just within the past few weeks. It reached them earlier than the timeline we'd promised. Then I received a phone call: "That's incredible. I want you to understand I truly valued that, and our business is yours moving forward." So the takeaway, I think, is this: sure, lengthy lead times put you at a competitive disadvantage — but only when your rivals are able to build the product, first of all. Certain products they can build; certain ones they cannot. Second, as we resolve these issues, customers genuinely want to partner with us. They recognize that we possess that know-how, that world-leading technology, that we're able to deliver for them. They see that we're putting close to $60 million into growing our Ogden facility. They know we're committed for the long term. So yes, I believe we have a robust business here provided we can deliver on our self-help, which we will. Hand it back over there.

Mark Jones analyst
#83

Mark Davies Jones from Stifel here. Just a quick question. I'm interested in when you've made the management changes. ETS appears to be performing a bit better and margins are heading upward. So why swap out the leadership there? And why bring in a person from Watson-Marlow, where there's presumably a great deal to do over the next 6 months as well?

Nimesh Patel executive
#84

What I'd say is this: when I think about my team, I feel enormous gratitude toward Armando for bringing the business to the point it reached in 3 years. We acquired 2 more businesses. Demand for the business has grown. We've taken on a new investment in an Ogden facility. So it makes me genuinely happy that he could accomplish all of that, and I'm thankful to him for it. That said, we're also considering how we expand the business going forward. Where do we take it next? What's required of us to deliver on those self-help programs? What's required of us to bring those 4 businesses together and ensure we extract the maximum from them? And Andrew is a person who -- you've witnessed the results delivered at Watson-Marlow, leaving the Biopharm issue to one side. What I mean is that's a fantastic business that has performed very well. His experience runs deep, not only in the U.S. but in Europe too. He has previously run manufacturing operations as well as sales operations. My confidence is very high that Andrew can deliver on that long-term promise we hold within ETS, including bringing our margins to the level we're aiming for.

Nimesh Patel executive
#85

That's why it falls to me to make this call and to ask Andrew to step into that position, and I'm genuinely glad that he's said yes to doing so.

Mark Jones analyst
#86

Regarding Watson-Marlow — is that the one you mean?

Nimesh Patel executive
#87

A search is already in progress for Andrew’s replacement. This also gives us a valuable chance to add new viewpoints to the executive team. Interim leadership is now in position while that process continues. Andrew leaves Watson-Marlow in a very strong position. The foundation there is really solid. We have invested in our manufacturing capacity. In manufacturing excellence and operations, Watson-Marlow is, I believe, further along than other areas of the business. Our global sales force has been built out. We have a highly appealing product portfolio. We simply need to push forward, and we need Biopharm demand to begin recovering, and that continues to be a fantastic business. So that is not a part of the portfolio <<inaudible>>. Let’s go to the back over there.

Tore Fangmann analyst
#88

Tore Fangmann here from Bank of America. I have 2 things. We began discussing how capacity limits in ETS have become more of a growth, shall we say, obstacle, and then there's demand. When do you expect those constraints could be removed so that we see the ETS pipe growing once more?

Nimesh Patel executive
#89

I'd say there are two constraints within ETS that we need to address to speed up growth further. We grew it quite impressively during the first half. The first constraint sits in the Industrial Equipment Heating portion of the business. We need to see Semicon demand pick up. The encouraging part is that our customers feel confident about placing larger orders toward the end of this year. I'd add a note of caution, though: we've heard that kind of thing before. So we'll believe it once it actually shows up. That said, I expect it to benefit sales next year rather than this year. So that's one piece of it — the demand side. When it comes to Industrial Process Heating, the key is delivering the operational improvements we've discussed. I believe that lands in next year. Even so, you'll see steady progress, and that will show up in our topline growth as we deliver it.

Tore Fangmann analyst
#90

All right, and then second, I’m not asking for ’25 guidance, but perhaps regarding the remaining 2 segments, where capacity matters less and demand matters more. If we talk about, say, preorders — basically, looking at the pipeline you currently have in those 2 segments (not backlog) — are you seeing a meaningful pickup there? As you just mentioned, we discussed Semis, but what about the other 2 segments: are we seeing a demand pickup there that isn’t reflected in orders right now?

Nimesh Patel executive
#91

In Watson-Marlow, as Biopharm recovers, we'd anticipate a pickup. For process industries inside Watson-Marlow, it hinges a great deal on how much IP growth we get next year. Honestly, that's really hard to predict right now. So it's — again, going back to the point I made earlier: we will beat IP, that's our aim, but there's no escaping IP. There's no escaping gravity. So next year's IP forecast will be a key growth driver for Watson-Marlow, and even more so for steam, since steam gets used in every industry, in every region of the world, and it's used in industrial processes. Its link to IP is even tighter than Watson-Marlow's is. So those are among the factors that will shape the growth profile for steam and Watson-Marlow next year. Who's next? I'll return to the phones after this question, to see whether there are any more — whether there are any questions on the phone.

Andrew Simms analyst
#92

Andrew Simms here, from Berenberg. I have one brief question. During your strategy remarks, you brought up how complex the business is. Given everything that has taken place with acquisitions across the last few years, is there any part of the group that no longer fits?

Nimesh Patel executive
#93

No. If you look at how I laid out the trends, I'd say there's a great deal of commonality among the group's businesses. Sure, each of the group businesses sells different products, but when it comes to what drives growth, the commonality is enormous. Keep in mind that steam has a very substantial pharmaceutical exposure, and that's not only at Watson-Marlow. So that's my first point. My second point, I think, is that across those 3 businesses the business model is exactly the same, and I believe we can extract more value yet from that business model in all 3 of them. So yes, the short answer to your question is no.

Andrew Simms analyst
#94

And just a quick one on ETS, I guess. Is there any underlying macro weakness that the order book is masking right now? I understand it has an order book and is therefore a bit different from the steam business, for example. But is there anything underlying in that business we should be aware of, particularly as we head toward the back end of this year and into 2025?

Nimesh Patel executive
#95

Yes, that’s a fair question. I’d say yes — unavoidably so — since what customers spend will be shaped by how they see their own business prospects and their financial condition. So when macroeconomic softness shows up, it affects our customers, and that in turn affects demand for us. That said, one point I’d make is this: unlike 10 years ago, perhaps, even when the macroeconomy is difficult, electrification aimed at cutting emissions remains a very important objective for our customers. And they are each progressing at different speeds regarding how strongly they concentrate on meeting those objectives. Where that objective matters a great deal, you will still see demand materialize. So we remain tied to macroeconomic strength or weakness, yet there is this extra force that goes somewhat beyond it.

Andrew Simms analyst
#96

And then last, since I still have the mic, just thinking about ETS once more going forward — do you see customers running into difficulties with their own projects? You clearly are somewhat bottlenecked. But when it comes to them securing electricity connections and considering power demand for their own businesses, over the medium term, will that prove a challenge given the competition for power, roughly speaking?

Nimesh Patel executive
#97

Yeah, absolutely. I mean, supporting electrification requires substantial investment in grids worldwide. Greening those grids also demands considerable investment, since moving from natural gas to electricity is only worthwhile when renewable electricity is available. Some of that work, especially among our bigger customers, will be handled by the customers themselves. They'll put money into renewable power at their own facilities. For smaller customers, though, who depend on the grid, greening it is necessary to bring their Scope 2 emissions down to 0. So we've discussed adoption rates before. How quickly customers take up some of these technologies will hinge on their capacity to finance it, and on how committed they are to hitting their emissions targets relative to their other priorities. It will hinge on their electricity access and what that access costs. And it will hinge on whether that's the right route, given that they have renewable power available. That's the reason this isn't something that happens overnight. This whole decarbonization electrification trend, I mean, will last 1, 2, 3 decades. Yet across that whole period, it will keep being an additional driver of our growth.

Nimesh Patel executive
#98

Let's go ahead and take a look at the phone lines. Sandra, are there any questions queued up there?

Operator operator
#99

We have 2 questions. The first comes from Mark Henderson, a shareholder.

Shareholder unknown
#100

At the start of this year, you put a modest amount into the Norwegian business Kyoto, which is now the target of that bid. Are you planning to collaborate with the incoming management team, or will you simply pocket a profit and exit?

Nimesh Patel executive
#101

Thanks, Mark. That's a genuinely good question. Yes, a bid exists. And as you probably know, we have representation on the Board. So we've been involved in that process from the start. What really matters to us in Kyoto is the partnership we have around their Heatcube design, development, and eventual manufacturing and sale. Because through Vulcanic, we supply a very critical piece of that technology via the heating elements. And so we've actually used the opportunity to solidify our commercial relationship with them. We're entirely comfortable keeping what was, as you likely remember, a very small economic stake in the company overall. But we've been speaking with the possible new owners about carrying that partnership forward, and they're very eager to do so, and so are we. And in fact, I'd go as far as saying our technology is genuinely important to their product. So it stays a really good investment for us. It wasn't one driven by financial returns on the initial investment we made, which is very small single-digit millions of pounds. It's more about the continuing relationship and the future demand it can create for us. Thank you, Mark.

Nimesh Patel executive
#102

I think -- does anyone else in the room have a question? Just one more? I believe -- that will be the final question we take, and after that, I think we'll finish up at that point.

Joshua Miller analyst
#103

Josh Miller at Morgan Stanley. I’ll keep this brief and ask about the softness in China. You brought up somewhat softer battery demand stemming from tariffs. Is that issue broader than batteries, or would you say it’s quite narrowly focused there?

Nimesh Patel executive
#104

Would you like to handle that?

Phil Scott executive
#105

Yes. I think tariffs were one item that stood out fairly significantly, which is why we brought it up—partly because, obviously, the buildup had been a pretty fast-growing sector. And then the drop-off caused by the tariffs—that buildup and decline were fairly extreme. We did mention it. But from a broader China standpoint, I think what we're seeing—as other businesses have pointed out—is what I'd describe, maybe, as a macroeconomic pivot, where China's economy, when it comes to investing for expansion, regrowth, and export, is beginning to turn somewhat more inward-looking. That fits with the globalization and tariff elements we discussed. So I think we're observing a broader pattern of reduced expansion in CapEx. And because of that, our team in China is pivoting toward concentrating on the process optimization side. And we have full confidence that the team will manage that successfully.

Nimesh Patel executive
#106

I mean, it's really just as Phil laid out — it comes down to EVs, and that's highlighted especially because of how fast things ramped up and then dropped off. But really, the broader picture is that sales trend in China, which quite frequently went toward expanding manufacturing capacity, since China was shipping goods worldwide. That's shifting now. So the team is putting more emphasis on process optimization and MRO these days. That's the fundamental trend in China, and that's the way we're adjusting our business to respond to it.

Joshua Miller analyst
#107

And maybe one more, a quick one on the TargetZero segments. Those solutions clearly get a lot of attention and a lot of innovation. When should we begin to expect that to start showing up in the top line and benefiting those divisions?

Nimesh Patel executive
#108

That probably won't meaningfully affect group-level top line for a couple of years, since we're still developing that technology. We're still learning from the pilots. We're still adapting the technology. There's also the challenge we mentioned earlier around customer adoption and when customers are ready to start thinking about how they invest behind their Net Zero roadmaps. So I think it will take some time to come through. So it's not something I'd expect to have a material impact this year, next year, certainly.

Joshua Miller analyst
#109

And maybe the final question is about that IP haircut, so to speak. How — I mean, could you perhaps share a bit more detail on just how large that haircut is? How conservative are you actually being when compared with those IP forecasts?

Nimesh Patel executive
#110

That's a reasonable question. It's quite hard to answer, though, since that isn't the way our forecasting works. We don't begin with an IP figure inside the forecast. What we actually do, especially within the year, is have each of our operating companies — and as I mentioned, we have more than 140 of them — build its own forecast from the bottom up. They look at what they've experienced in the first half, conditions in their local economy, what their customers are saying, and so on and so forth, and there's a really tight link between the way they forecast and what shows up in IP. For us as management, that's the yardstick for judging whether the forecasts we're getting form a sensible set or are too rosy or too gloomy. So it isn't as though there's a single IP figure you can glance at and declare correct. What we have done, though, through discussions with the businesses, and their discussions with their regions, and those regions' discussions with their countries, is to make the point that we shouldn't lean too hard on where those IP figures sit for the second half. We aren't convinced they'll come through. Pay more attention to what customers are telling you, pay more attention to what your salespeople in the field are hearing, and keep things appropriately balanced.

Nimesh Patel executive
#111

And naturally, in certain instances, we raise the forecast. In certain instances, we lower them. That's simply — that's just human nature when it comes to forecasting, and getting the calibration right is our job. So other than saying it isn't the full — it is an improvement in second half IP, it isn't the full scale of that improvement, there's no single number I could give you. Thank you, and thanks to all of you for joining us today. I appreciate it. And I know we've held you a little longer than usual. Thank you, and have a lovely summer all day. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Spirax Group plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Spirax Group plc earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.